©
Getty Images
Conducted in Oxford, the trial will assess the safety and immune response of the ChAdOx1 BDBV vaccine in 50 healthy adults aged 18–55 years. Recruitment of volunteers into the study is now underway, where they will then attend screening visits. In the coming weeks, and following regulatory review for trial commencement, participants will then be vaccinated and attend follow-up visits in Oxford.
To support the rapid launch of the study and progression of the vaccine candidate into clinical evaluation, Serum Institute of India (SII) has manufactured and stockpiled approximately 620,000 doses of the ChAdOx1 BDBV vaccine candidate in two weeks for potential future use and has supplied 4,000 investigational doses for this Phase I trial.
This work is supported by funding from the Coalition for Epidemic Preparedness Innovations (CEPI), to the University of Oxford and SII, as part of a US$8.6 million programme to advance the development of Bundibugyo vaccines. The programme builds on CEPI’s strategic partnership with the University of Oxford and SII’s participation in CEPI’s Vaccine Manufacturing Facility Network.
Subject to regulatory approval, preparations are also underway for further clinical studies with our partners, including those at the Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit.
The ChAdOx1 BDBV vaccine was developed by scientists at the University of Oxford’s Oxford Vaccine Group and Pandemic Sciences Institute and uses the same viral vector platform as the Oxford/AstraZeneca COVID-19 vaccine, which is estimated to have saved over six million lives during its first year of use.